Akari Therapeutics announced the upcoming presentation of a case study, Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, on Sunday, April 23rd at 8:30 am. The poster presentation will take place at The European Society for Blood and Marrow Transplantation in Paris, France. Nomacopan is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy advancing into pivotal Part B later this year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKTX:
- Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
- Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
- Akari Therapeutics announces $4M registered direct offering
- Akari announces Poland, U.K. approve new manufacturing process for nomacopan
- Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings
